Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in ...

CG Oncology (NASDAQ:CGON – Get Free Report) is projected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) ...

Anktiva (nogapendekin alfa inbakicep, or N-803) can be used in combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients who had not responded to the BCG shot on its ...

Net research and development expenses for the device division increased in 2024 to CAD175,000 from CAD44,000 in 2023, a 400% increase. The increase is attributed to development of a new software ...

The FDA application is for the use of TAR-200 as a treatment for high-risk, non-muscle-invasive bladder cancer (NMIBC) that does not respond to BCG, a live bacterial vaccine that is the standard ...

that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S. CULVER CITY, Calif., February 13, 2025--ImmunityBio, Inc. (NASDAQ ...

Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have received a consensus rating of “Buy” from the ten ...

The program, implemented through a partnership between ImmunityBio and the Serum Institute of India, is intended to address the ongoing BCG shortage by providing an alternative source of the therapy ...

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for ...